Alexandria Real Estate Equities (ARE) to Announce Q4 Earnings on January 26 with FFO Estimate of $2.14
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Earnings Announcement: Alexandria Real Estate Equities is set to release its Q4 earnings on January 26 after market close, with investors keenly awaiting insights into its financial performance and future guidance.
- FFO Estimate: The consensus estimate for funds from operations (FFO) stands at $2.14 per share, indicating a cautious outlook from investors, particularly following a significant 45% dividend cut.
- Revenue Estimate: The anticipated revenue for Q4 is $742.64 million, reflecting market expectations for revenue growth, although this may be tempered by the recent dividend reduction's negative implications.
- Market Reaction: The dividend cut has spooked investors, leading to concerns about Alexandria's future performance and potentially increasing stock price volatility as market confidence wanes.
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARE is 51.53 USD with a low forecast of 15.84 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
4 Buy
11 Hold
0 Sell
Moderate Buy
Current: 58.090
Low
15.84
Averages
51.53
High
67.00
Current: 58.090
Low
15.84
Averages
51.53
High
67.00
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
